Sanofi reports positive data from Phase III trial of Dupixent

Sanofi has reported positive data from a Phase III clinical trial of Dupixent (dupilumab) in children aged one to 11 years with eosinophilic oesophagitis (EoE).

The double-blind, placebo-controlled, randomised trial assessed the safety and efficacy of Dupixent for up to 52 weeks.